Hold onto your seats, beauty and skincare enthusiasts, because L’Oréal is doubling down on its commitment to the world of dermatology and aesthetics—and this move is set to shake up the industry. In a bold strategic play, L’Oréal is increasing its stake in Galderma, the global dermatology powerhouse, to a solid 20 percent. But here’s where it gets intriguing: this isn’t just a financial transaction; it’s a testament to the evolving landscape of beauty and healthcare, where aesthetics and science are merging like never before.
From its Paris headquarters, L’Oréal announced it’s acquiring an additional 10 percent stake in Galderma Group AG, a leader in pure-play dermatology and one of the largest players in injectable aesthetics. This move builds on L’Oréal’s original co-founding role in Galderma, solidifying its position in a market that’s booming. The deal is being struck with a consortium led by EQT, which includes heavyweights like Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte Ltd. While the exact price tag remains under wraps, the implications are crystal clear: L’Oréal is serious about dominating the dermatological beauty space.
But here’s where it gets controversial: Is L’Oréal’s growing stake in Galderma a strategic masterstroke or a risky bet on a market that’s already crowded with players? Some analysts argue that while Galderma’s growth is impressive, the dermatological beauty market is fiercely competitive. Others believe L’Oréal’s move is a no-brainer, given the sector’s explosive growth—the global injectable aesthetics market alone is projected to soar from $9.45 billion in 2023 to $18.12 billion by 2032, according to Introspective Market Research. So, is L’Oréal ahead of the curve, or is it playing catch-up? Let’s dive deeper.
L’Oréal’s CEO, Nicolas Hieronimus, framed the move as a natural extension of the company’s core beauty business. “Aesthetics is a key adjacency to our core beauty business that we are keen to continue to explore,” he stated. “Our initial strategic investment in Galderma in 2024 has proven very successful, and we’re eager to solidify and extend this partnership further.” But this isn’t just about financial gains—it’s about innovation. Galderma’s CEO, Flemming Ørnskov, highlighted the company’s “impressive growth, strong innovation, and category leadership” in dermatology. With L’Oréal’s backing, Galderma aims to scale into a full-fledged dermatology powerhouse, focusing on consumer-centric innovation and portfolio expansion.
And this is the part most people miss: While L’Oréal insists it’s not planning to increase its stake further, analysts are buzzing about the potential for L’Oréal to eventually gain full control over Galderma’s therapeutic dermatology franchise, particularly once the value of assets like Nemluvio becomes clearer. Jefferies equity analyst Benjamin Jackson noted, “We continue to see the possibility of L’Oréal gaining full control... but this would likely take time.” Could this be L’Oréal’s long game? Or is it content with its current level of influence?
The transaction, expected to close by the first quarter of 2026, will be funded through L’Oréal’s available cash and credit lines. It’s a significant move, but one that aligns with L’Oréal’s broader strategy. In 2023, the company rebranded its Active Cosmetics division to Dermatological Beauty, signaling its ambition to become the go-to partner for dermatologists worldwide. With brands like CeraVe, La Roche-Posay, and SkinCeuticals under its belt, L’Oréal’s Dermatological Beauty division has been a standout performer, growing 3.4 percent in the first nine months of this year.
Here’s the kicker: Galderma’s transformation from a primarily therapeutic company to a dermatology giant mirrors L’Oréal’s own evolution. Eleven years ago, Galderma was a €1.6 billion company; today, it’s a €4.4 billion behemoth, with most of its revenue coming from injectable aesthetics and dermatological skincare. Meanwhile, the procedures market has grown sixfold, creating a ripe opportunity for L’Oréal to capitalize on its scientific partnership with Galderma. This partnership, announced in 2024, leverages Galderma’s expertise in dermatological solutions and L’Oréal’s prowess in skin biology and diagnostic tools.
As part of the deal, Galderma’s board will consider appointing two non-independent board candidates from L’Oréal, replacing the EQT-led consortium starting in 2026. This move underscores L’Oréal’s growing influence over Galderma’s strategic direction. But the question remains: Will this partnership propel both companies to new heights, or will it dilute Galderma’s independence?
What do you think? Is L’Oréal’s increased stake in Galderma a game-changer, or is it overreaching in an already saturated market? And could this be the beginning of L’Oréal’s dominance in dermatological beauty, or is there a limit to how much influence it can wield? Share your thoughts in the comments—this is one conversation you won’t want to miss!
